Company Tenax Therapeutics Inc Nasdaq
Equities
US88032L1008
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 21-07-13 | |
Director of Finance/CFO | 69 | Jan. 10 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Doug Randall
COO | Chief Operating Officer | - | 13-11-13 |
Douglas Hay
LAW | General Counsel | - | 13-11-13 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 14-04-03 |
June Almenoff
BRD | Director/Board Member | 67 | 21-02-24 |
Declan Doogan
BRD | Director/Board Member | 72 | 21-02-24 |
Michael Davidson
BRD | Director/Board Member | 67 | 21-02-24 |
Robyn Hunter
BRD | Director/Board Member | 62 | 22-01-27 |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 21-01-14 |
Chief Executive Officer | 50 | 21-07-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 210 | 0 | 0 | 99.65 % |
Stock B | 1 | 1,958,245 | 1,951,297 ( 99.65 %) | 0 |
Company contact information
Tenax Therapeutics, Inc.
101 Glen Lennox Drive Suite 300
27517, Chapel Hill
+(919) 855-2100
http://www.tenaxthera.com![address Tenax Therapeutics Inc](https://cdn.zonebourse.com/static/address/18045260.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |